Clinical trial
Isotretinoin Plus Dexamethasone in Treating Patients With Multiple Myeloma
NCT00021359 · Fox Chase Cancer Center, Other · Completed
Key facts
| NCT number | NCT00021359 |
|---|---|
| Title | Isotretinoin Plus Dexamethasone in Treating Patients With Multiple Myeloma |
| Official title | A Phase II Trial of Dexamethasone and 13-cis-Retinoic Acid as First-Line Treatment for Multiple Myeloma |
| Lead sponsor | Fox Chase Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Drug |
| Interventions | dexamethasone, isotretinoin |
| Enrollment | 17 |
| Start date | Aug 1, 1999 |
| Primary completion | Jul 1, 2000 |
| Completion | Oct 1, 2005 |
| First posted | Mar 11, 2004 |
| Last update posted | Jul 10, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: